Preparing for pandemics: a systematic review of pandemic influenza clinical management guidelines.
AGREE II
Clinical management guidelines
Influenza
Pandemic
Preparedness
Supportive care
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
07 11 2022
07 11 2022
Historique:
received:
10
01
2022
accepted:
19
10
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
10
11
2022
Statut:
epublish
Résumé
The COVID-19 pandemic has highlighted the importance of evidence-based clinical decision-making. Clinical management guidelines (CMGs) may help reduce morbidity and mortality by improving the quality of clinical decisions. This systematic review aims to evaluate the availability, inclusivity, and quality of pandemic influenza CMGs, to identify gaps that can be addressed to strengthen pandemic preparedness in this area. Ovid Medline, Ovid Embase, TRIP (Turning Research Into Practice), and Guideline Central were searched systematically from January 2008 to 23rd June 2022, complemented by a grey literature search till 16th June 2022. Pandemic influenza CMGs including supportive care or empirical treatment recommendations were included. Two reviewers independently extracted data from the included studies and assessed their quality using AGREE II (Appraisal of Guidelines for Research & Evaluation). The findings are presented narratively. Forty-eight CMGs were included. They were produced in high- (42%, 20/48), upper-middle- (40%, 19/48), and lower-middle (8%, 4/48) income countries, or by international organisations (10%, 5/48). Most CMGs (81%, 39/48) were over 5 years old. Guidelines included treatment recommendations for children (75%, 36/48), pregnant women (54%, 26/48), people with immunosuppression (33%, 16/48), and older adults (29%, 14/48). Many CMGs were of low quality (median overall score: 3 out of 7 (range 1-7). All recommended oseltamivir; recommendations for other neuraminidase inhibitors and supportive care were limited and at times contradictory. Only 56% (27/48) and 27% (13/48) addressed oxygen and fluid therapy, respectively. Our data highlights the limited availability of up-to-date pandemic influenza CMGs globally. Of those identified, many were limited in scope and quality and several lacked recommendations for specific at-risk populations. Recommendations on supportive care, the mainstay of treatment, were limited and heterogeneous. The most recent guideline highlighted that the evidence-base to support antiviral treatment recommendations is still limited. There is an urgent need for trials into treatment and supportive care strategies including for different risk populations. New evidence should be incorporated into globally accessible guidelines, to benefit patient outcomes. A 'living guideline' framework is recommended and further research into guideline implementation in different resourced settings, particularly low- and middle-income countries.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has highlighted the importance of evidence-based clinical decision-making. Clinical management guidelines (CMGs) may help reduce morbidity and mortality by improving the quality of clinical decisions. This systematic review aims to evaluate the availability, inclusivity, and quality of pandemic influenza CMGs, to identify gaps that can be addressed to strengthen pandemic preparedness in this area.
METHODS
Ovid Medline, Ovid Embase, TRIP (Turning Research Into Practice), and Guideline Central were searched systematically from January 2008 to 23rd June 2022, complemented by a grey literature search till 16th June 2022. Pandemic influenza CMGs including supportive care or empirical treatment recommendations were included. Two reviewers independently extracted data from the included studies and assessed their quality using AGREE II (Appraisal of Guidelines for Research & Evaluation). The findings are presented narratively.
RESULTS
Forty-eight CMGs were included. They were produced in high- (42%, 20/48), upper-middle- (40%, 19/48), and lower-middle (8%, 4/48) income countries, or by international organisations (10%, 5/48). Most CMGs (81%, 39/48) were over 5 years old. Guidelines included treatment recommendations for children (75%, 36/48), pregnant women (54%, 26/48), people with immunosuppression (33%, 16/48), and older adults (29%, 14/48). Many CMGs were of low quality (median overall score: 3 out of 7 (range 1-7). All recommended oseltamivir; recommendations for other neuraminidase inhibitors and supportive care were limited and at times contradictory. Only 56% (27/48) and 27% (13/48) addressed oxygen and fluid therapy, respectively.
CONCLUSIONS
Our data highlights the limited availability of up-to-date pandemic influenza CMGs globally. Of those identified, many were limited in scope and quality and several lacked recommendations for specific at-risk populations. Recommendations on supportive care, the mainstay of treatment, were limited and heterogeneous. The most recent guideline highlighted that the evidence-base to support antiviral treatment recommendations is still limited. There is an urgent need for trials into treatment and supportive care strategies including for different risk populations. New evidence should be incorporated into globally accessible guidelines, to benefit patient outcomes. A 'living guideline' framework is recommended and further research into guideline implementation in different resourced settings, particularly low- and middle-income countries.
Identifiants
pubmed: 36345005
doi: 10.1186/s12916-022-02616-6
pii: 10.1186/s12916-022-02616-6
pmc: PMC9640791
doi:
Substances chimiques
Oseltamivir
20O93L6F9H
Antiviral Agents
0
Types de publication
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
425Subventions
Organisme : Medical Research Council
ID : MR/T001151/1
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
East Mediterr Health J. 2011 Apr;17(4):342-8
pubmed: 22259894
J Thorac Dis. 2011 Dec;3(4):274-89
pubmed: 22263103
Ann Intern Med. 2020 Oct 20;173(8):662-663
pubmed: 32673059
Crit Care. 2015 Feb 20;19:46
pubmed: 25888424
Pediatr Neonatol. 2010 Feb;51(1):1-4
pubmed: 20225530
Clin Ther. 2018 Aug;40(8):1268-1281
pubmed: 30077340
Lancet Reg Health Eur. 2021 Jun;5:100104
pubmed: 33969337
Med J Aust. 2009 Aug 3;191(3):142-5
pubmed: 19645641
Am J Public Health. 2018 Nov;108(11):1449-1454
pubmed: 30252528
BMC Health Serv Res. 2018 Feb 27;18(1):143
pubmed: 29482555
Maturitas. 2021 Jul;149:56-58
pubmed: 33579552
Implement Sci. 2014 Jan 02;9:3
pubmed: 24383701
Med Intensiva. 2012 Mar;36(2):103-37
pubmed: 22245450
BMJ. 2020 Aug 3;370:m3001
pubmed: 32747332
JAMA Netw Open. 2021 May 3;4(5):e218828
pubmed: 33938933
Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965
pubmed: 24718923
PLoS Med. 2013 Nov;10(11):e1001558
pubmed: 24302890
BMC Med. 2019 Sep 6;17(1):170
pubmed: 31488138
BMJ. 2021 Apr 29;373:n1093
pubmed: 33926903
J Clin Epidemiol. 2019 Apr;108:64-76
pubmed: 30529647
Pneumologie. 2009 Aug;63(8):417-25
pubmed: 19670099
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Bone Res. 2020 Feb 14;8:8
pubmed: 32128276
Intensive Care Med. 2020 Feb;46(2):153-162
pubmed: 31912206
Clinics (Sao Paulo). 2009;64(10):1015-24
pubmed: 19841710
Microorganisms. 2020 May 21;8(5):
pubmed: 32455845
Lancet. 2020 Jan 4;395(10217):42-52
pubmed: 31839279
Anesth Analg. 2020 Jul;131(1):86-92
pubmed: 32243287
Clin Trials. 2015 Oct;12(5):503-10
pubmed: 26374681
J Gynecol Obstet Biol Reprod (Paris). 2009 Dec;38(8):615-28
pubmed: 19879070
CMAJ. 2010 Dec 14;182(18):E839-42
pubmed: 20603348
Singapore Med J. 2009 Jun;50(6):567-80
pubmed: 19551308
Ann Intern Med. 2021 Aug;174(8):1151-1158
pubmed: 34125574
Mil Med. 2005 Mar;170(3):243-6
pubmed: 15828703
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
BMJ Open. 2021 Mar 10;11(3):e043887
pubmed: 33692181
Ann Saudi Med. 2010 Jan-Feb;30(1):1-10
pubmed: 20103951
Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1201-1208
pubmed: 32056049
N Engl J Med. 2016 Feb 18;374(7):636-46
pubmed: 26886522
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
MMWR Recomm Rep. 2011 Jan 21;60(1):1-24
pubmed: 21248682
BMJ. 2020 May 26;369:m1936
pubmed: 32457027
Ig Sanita Pubbl. 2009 Mar-Apr;65(2):139-56
pubmed: 19529045
PLoS One. 2019 Jan 25;14(1):e0210982
pubmed: 30682097
Zoonoses Public Health. 2020 May;67(3):203-212
pubmed: 31930694
Infection. 2021 Oct;49(5):889-905
pubmed: 34170486
Eur Respir Rev. 2021 Feb 9;30(159):
pubmed: 33568526
Am J Respir Crit Care Med. 2011 May 1;183(9):1200-6
pubmed: 21471082
Nature. 2019 Sep;573(7774):S54-S55
pubmed: 31534252
BMJ. 1999 Feb 20;318(7182):527-30
pubmed: 10024268